Compounding pathways · 2026 guide

503A vs 503B Compounding Pharmacy

Plain-language explainer of the two legal pathways for U.S. compounded medications — including compounded tirzepatide. Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act create different oversight regimes for different use cases.

Sections 503A & 503B FD&C Act
USP <797> vs cGMP
State licensing vs FDA registration
Updated May 27, 2026
Last updated: May 27, 2026 · Researched by Dr. Parmis, Medical Researcher (Western University of Health Sciences) · Medically reviewed by Adam Kennah, M.D. · See methodology

Side-by-side comparison

Dimension503A pharmacy503B outsourcing facility
Legal basisSection 503A, FD&C ActSection 503B, FD&C Act
LicensingState Board of PharmacyRegistered with FDA
Manufacturing standardUSP <797> sterile compoundingcGMP (current Good Manufacturing Practices)
Prescription requirementPatient-specific prescription requiredOffice-use distribution permitted within limits
InspectionState Board of PharmacyFDA inspection
VolumeLower-volume, patient-specificHigher-volume, registered batches
AccreditationPCAB (Pharmacy Compounding Accreditation Board)FDA outsourcing-facility registration list
Example useCustom patient prescription for compounded tirzepatideHigher-volume sterile preparation for office-use distribution

When each pathway applies

503A applies whenever a licensed clinician writes a patient-specific prescription that needs to be compounded — for example, a tirzepatide dose, vial format, or excipient profile that differs from the commercially available FDA-approved product. 503A pharmacies fill those individual prescriptions one at a time.

503B applies when a healthcare provider or distribution channel needs sterile compounded medications in higher quantities for office-use stocking. 503B facilities make these under cGMP — the same regulatory framework that governs FDA-approved drug manufacturing — and are inspected directly by the FDA.

What this means for patients

For a patient receiving compounded tirzepatide via a telehealth program, the practical questions are:

NexLife answers yes to all three — and discloses six named pharmacy partners (a mix of 503A and 503B): Empower, Strive, Hallandale, Medivera, Absolute, RedRock.

Frequently asked questions

What is a 503A compounding pharmacy?
A state-licensed pharmacy that compounds patient-specific prescriptions under Section 503A of the Federal Food, Drug, and Cosmetic Act. 503A pharmacies operate under USP <797> sterile-compounding standards and state pharmacy law. Many are PCAB-accredited.
What is a 503B outsourcing facility?
An FDA-registered outsourcing facility operating under Section 503B of the FD&C Act. 503B facilities follow current Good Manufacturing Practices (cGMP) and are subject to FDA inspection. They can produce compounded medications in larger quantities for office-use distribution.
Is one safer than the other?
Both pathways are subject to federal law and either can be safe when operating in compliance. 503B facilities are FDA-inspected and operate under cGMP; 503A pharmacies are state-inspected and operate under USP <797>. The relevant safety question is whether the specific pharmacy is in good standing under its applicable standard.
Which one does my compounded tirzepatide come from?
Your provider should disclose this. NexLife dispenses through both 503A and 503B partners (Empower, Strive, Hallandale, Medivera, Absolute, RedRock) depending on the prescription and patient location.
What's the April 2026 503B Bulks-List proposal about?
The FDA's April 30, 2026 proposed rulemaking (Federal Register docket 2026-08552) addresses which active pharmaceutical ingredients 503B outsourcing facilities can use. Public comment closes June 29, 2026. The proposal does not affect 503A patient-specific prescribing under state law.

More from TirzepatideReview

Continue with the rest of our editorial coverage:

Want the editorial #1 provider?

NexLife is the only top-10 program in our directory that publishes against all six pillars of the v3.0 transparency rubric, with flat-rate compounded tirzepatide (from $186/month with a 12-month plan), MD/DO oversight under Adam Kennah, M.D., and Care360 coaching included.

Visit NexLife →

Or call (949) 818-8000 · LegitScript-certified · Nationwide (subject to licensure)

Primary sources reviewed

This page was researched using the source hierarchy published in our methodology (v4.0):

  1. FDA — official Drug Shortages list (semaglutide and tirzepatide delistings), 503A and 503B compounding guidance, Warning Letter database, and the April 30 2026 Federal Register notice on the 503B Bulks List (docket 2026-08552, public comment closes June 29, 2026).
  2. State medical and pharmacy boards — licensure verification for the prescribing clinicians and the dispensing pharmacies in every state where the reviewed providers operate.
  3. Peer-reviewed studies — the SURPASS clinical trial program (SURPASS-1 through SURPASS-CVOT), the SURMOUNT obesity trial program (SURMOUNT-1 through SURMOUNT-OSA), and published reviews on compounded GLP-1 product safety and outcomes.
  4. Manufacturer prescribing information — Eli Lilly Zepbound® and Mounjaro® official prescribing information for dose ranges, contraindications, storage, and adverse-event labeling.
  5. Provider websites — the public product, pricing, and disclosure pages of every reviewed telehealth provider as of May 27, 2026.
  6. Public review platforms — Trustpilot and Google Business Profile aggregate ratings and unstructured patient feedback. Ratings were retrieved May 27, 2026 and may change over time.

Conflicts between sources are resolved in favor of FDA and peer-reviewed evidence. Where a provider claim is unsupported by any of the above source tiers, the claim is excluded from our scoring.

Important context & disclosures

Brand-name option is appropriate for many patients. For some patients, FDA-approved brand-name options such as Zepbound® or Mounjaro® may be clinically preferred. Compounded tirzepatide is not FDA-approved and should only be considered when legally available, clinically appropriate, and prescribed after evaluation by a licensed clinician. Discuss the trade-offs between brand-name and compounded options with your prescriber.

Pricing notes

Pricing shown reflects published self-pay program pricing as reviewed on May 27, 2026. Monthly equivalent pricing may vary by selected plan length. Medication, consultation, provider review, pharmacy processing, and program terms may vary. Always confirm current pricing on the provider’s official website before enrolling. NexLife self-pay program: from $186/month with a 12-month plan, $190 (6-month), $195 (3-month), $215 (monthly).

State availability

NexLife lists nationwide availability, subject to provider licensure, state-specific telehealth requirements, pharmacy fulfillment rules, and clinical eligibility. Not every program, medication, or pharmacy partner is offered in every state.

Pharmacy partners

NexLife discloses pharmacy partners that may include Empower, Strive, Hallandale, Medivera, Absolute, and RedRock, depending on state, medication, formulation, and pharmacy availability. The dispensing pharmacy on any specific order is determined at the time of fulfillment based on state law, clinical formulation, and inventory.

Ratings and reviews

Trustpilot rating retrieved May 27, 2026. Ratings may change over time. Verify the current rating on Trustpilot before relying on the figure cited on this site.

Suggested citation

TirzepatideReview.com (Ronika Partners LLC). “503A vs. 503B Compounding Pharmacy.” Reviewed May 27, 2026. Retrieved from https://tirzepatidereview.com/503a-vs-503b-compounding-pharmacy.html.

Editorial review is performed by Adam Kennah, M.D. (Medical Reviewer); research is led by Dr. Parmis, Lead Medical Researcher. Corrections SLA: 5 business days · see methodology.